Last updated: September 8, 2026
Ceftobiprole medocaril sodium, marketed in the United States as Zevtera by Basilea Pharmaceutica, entered the U.S. market in 2024 as a hospital-focused cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA). Its commercial opportunity is concentrated in serious bloodstream, endocarditis, skin-structure, and community-acquired pneumonia infections.
The product has a differentiated clinical profile but faces a difficult pricing environment. Its principal risks are hospital antimicrobial-stewardship restrictions, competition from low-cost generic vancomycin and daptomycin, limited U.S. commercial infrastructure, and eventual generic entry after patent and regulatory protections expire.
What is ceftobiprole medocaril sodium used for?
Ceftobiprole medocaril is an intravenous prodrug converted in the body to the active cephalosporin ceftobiprole. It binds penicillin-binding proteins and has activity against Gram-positive pathogens, including MRSA, as well as selected Gram-negative organisms.
The FDA approved Zevtera on March 14, 2024, for three adult indications:
| FDA indication |
Patient population |
| Staphylococcus aureus bacteremia |
Adults, including those with right-sided infective endocarditis |
| Acute bacterial skin and skin-structure infections |
Adults and pediatric patients aged 3 months and older |
| Community-acquired bacterial pneumonia |
Adults |
The bacteremia approval is commercially important because it places ceftobiprole in a high-acuity treatment segment where physicians seek alternatives to vancomycin and daptomycin. The FDA approval was supported by Phase 3 studies in bacteremia, skin infections, and community-acquired bacterial pneumonia. The product had previously been approved outside the United States under the Mabelio and Zevtera brands. (FDA, 2024a; Basilea Pharmaceutica, 2024a)
How does ceftobiprole compare with vancomycin, daptomycin, and ceftaroline?
Ceftobiprole competes primarily on spectrum, bactericidal activity, and potential treatment convenience rather than price.
| Drug |
Main role in serious MRSA infection |
Key commercial advantage |
Principal limitation |
| Ceftobiprole |
MRSA bacteremia, right-sided endocarditis, skin infections, community-acquired pneumonia |
Broad cephalosporin spectrum and bacteremia label |
Intravenous hospital use; high acquisition cost versus generics |
| Vancomycin |
Broad first-line MRSA treatment |
Very low generic cost and extensive clinical experience |
Therapeutic drug monitoring, nephrotoxicity, slower operational workflow |
| Daptomycin |
MRSA bacteremia and right-sided endocarditis |
Once-daily dosing and strong bacteremia positioning |
Not used for pneumonia because pulmonary surfactant inactivates it |
| Ceftaroline |
MRSA skin infections and pneumonia |
Broad cephalosporin profile and MRSA activity |
Less established bacteremia positioning; dosing frequency and cost |
| Linezolid |
MRSA pneumonia and selected skin infections |
Oral formulation |
Bacteriostatic activity and hematologic or drug-interaction concerns |
Ceftobiprole’s most defensible niche is complicated MRSA bacteremia in patients who require broad intravenous beta-lactam coverage or who cannot tolerate vancomycin. Its pneumonia indication differentiates it from daptomycin, but hospital formularies may still favor generic beta-lactams, vancomycin, or linezolid.
What is the U.S. market opportunity for Zevtera?
The addressable market is substantial in patient volume but narrower in revenue terms because Zevtera is primarily an inpatient rescue or targeted therapy.
The largest commercial opportunity is S. aureus bacteremia. The condition involves prolonged hospitalization, frequent infectious-disease consultation, repeat blood cultures, and substantial use of intravenous antibiotics. Right-sided infective endocarditis increases clinical severity and treatment duration.
The main market segments are:
- MRSA bacteremia and right-sided endocarditis.
- Hospitalized adults with acute bacterial skin and skin-structure infections.
- Adults with community-acquired bacterial pneumonia requiring intravenous therapy.
- Pediatric skin and respiratory infections, where the FDA label expands potential use but does not guarantee formulary adoption.
U.S. revenue depends on several factors:
- Inclusion in hospital formularies.
- Infectious-disease physician familiarity.
- Demonstration of value against vancomycin and daptomycin.
- Use in patients with renal impairment or treatment intolerance.
- Hospital antimicrobial-stewardship restrictions.
- Basilea’s ability to build sales coverage and contracting relationships.
Zevtera is unlikely to displace generic vancomycin broadly. Its more realistic commercial trajectory is as a targeted branded antibiotic used when clinicians value its spectrum, bacteremia evidence, or operational advantages.
What is the financial trajectory for ceftobiprole medocaril sodium?
Basilea’s commercial portfolio is led by Cresemba, its antifungal product, while Zevtera is the company’s second marketed product. Basilea does not report Zevtera as a separately listed public company, so product-level revenue analysis relies on brand-level disclosures and management commentary.
The U.S. launch created a new growth channel in 2024. Before that launch, Zevtera revenue came largely from European and other international markets through direct sales and licensing arrangements.
| Financial driver |
Directional effect on Zevtera |
| U.S. launch in 2024 |
Increases addressable revenue and product visibility |
| Three FDA-approved indications |
Supports broader hospital access than a single-indication antibiotic |
| QIDP designation |
Extends certain U.S. regulatory and patent protections |
| Generic hospital antibiotics |
Limits pricing power |
| Basilea commercial infrastructure |
Creates execution costs and launch investment |
| International licensing |
Reduces direct commercialization burden but limits retained economics |
| Antibiotic stewardship |
Restricts routine or prophylactic use |
Basilea reported strong growth in total product sales after the U.S. launch, although Cresemba remained the larger contributor. Zevtera’s financial profile is therefore best analyzed as a growth product within a diversified specialty-pharmaceutical portfolio rather than as a standalone blockbuster candidate. (Basilea Pharmaceutica, 2024b; Basilea Pharmaceutica, 2025)
The likely revenue pattern is a staged ramp:
- Early launch: hospital formulary review, limited stocking, and use in complex patients.
- Expansion phase: wider adoption in infectious-disease departments and treatment protocols.
- Mature phase: recurring use in bacteremia, endocarditis, and selected pneumonia cases.
- Post-exclusivity phase: price erosion and conversion to generic or authorized-generic supply.
A high-value commercial outcome would require sustained use in bacteremia and endocarditis. Skin infections and pneumonia can expand volume but are more exposed to inexpensive alternatives.
When does ceftobiprole lose U.S. exclusivity?
The regulatory and patent exclusivity analysis is more complex than a single expiration date.
Ceftobiprole was approved in several non-U.S. markets before its U.S. approval. That history reduces the likelihood that the U.S. product receives the standard five-year new chemical entity exclusivity available to a genuinely new active ingredient first approved in the United States.
Zevtera received Qualified Infectious Disease Product designation under the Generating Antibiotic Incentives Now Act. QIDP status provides an additional five years of certain exclusivity or patent-term protection, subject to the statutory framework and the specific protection attached to the product. (FDA, 2024b)
The principal U.S. protection layers are:
| Protection |
Relevance to Zevtera |
| QIDP designation |
Adds five years to certain applicable exclusivity or patent protections |
| Drug patent claims |
May cover ceftobiprole, salts, prodrugs, formulations, or manufacturing processes |
| FDA regulatory exclusivity |
Depends on the approved application and clinical evidence |
| Method-of-use patents |
May protect specific approved uses if listed and enforceable |
| Pediatric exclusivity |
May apply only if FDA grants it after completion of an accepted pediatric study |
A definitive generic-entry date requires review of the current FDA Orange Book, issued patents, terminal disclaimers, patent-term adjustment, pediatric extensions, and any Paragraph IV litigation. The U.S. approval date alone does not establish the end of all market protection.
What patents protect ceftobiprole medocaril sodium?
The relevant patent estate is expected to include several technical categories:
Active pharmaceutical ingredient and prodrug patents
These claims may cover ceftobiprole medocaril, specific salts, stereochemical forms, crystalline forms, or pharmaceutical compositions. Composition claims normally provide the strongest barrier if they remain enforceable and are not invalidated.
Formulation patents
Formulation protection may cover:
- Intravenous reconstitution systems.
- Stable aqueous or lyophilized formulations.
- Specific pH ranges.
- Infusion concentrations.
- Storage conditions.
- Pharmaceutical compositions containing ceftobiprole medocaril sodium.
Formulation patents generally provide narrower protection than composition patents. Their value depends on whether a generic applicant can design around the claims while producing an equivalent injectable product.
Method-of-use patents
Use claims may cover treatment of:
- S. aureus bacteremia.
- Right-sided infective endocarditis.
- Acute bacterial skin and skin-structure infections.
- Community-acquired bacterial pneumonia.
- Resistant Gram-positive infections.
Method-of-use patents can delay a fully labeled generic launch but may not prevent an initial approval with indications carved out. Enforcement depends on the generic label, prescribing behavior, inducement evidence, and the scope of any FDA-listed use patent.
Manufacturing patents
Manufacturing claims can protect synthesis of the medocaril prodrug, purification, impurity control, solid-state properties, and sterile injectable production. These patents may raise technical barriers but do not always prevent generic competition if an alternative process is available.
What is the Orange Book status of Zevtera?
Zevtera is an FDA-approved prescription drug marketed under NDA review. Its Orange Book position determines whether generic applicants must certify against listed patents and whether those certifications can trigger litigation.
The relevant generic pathways are:
- Paragraph IV certification that a listed patent is invalid, unenforceable, or will not be infringed.
- Paragraph III certification agreeing to wait until patent expiration.
- Section viii statement carving out a patented method of use.
- ANDA approval after resolution or expiration of applicable protections.
The commercial importance of Orange Book listings depends on whether Basilea or its partners list broad composition patents, narrower formulation patents, or only method-of-use claims. A strong Orange Book position can create a litigation stay of up to 30 months after a timely patent-infringement action. (FDA, 2024c)
Which companies are likely to challenge Zevtera?
Potential challengers include large injectable-generic manufacturers and specialty sterile-drug companies with experience in hospital antibiotics. The most likely candidates are companies with:
- Existing cephalosporin manufacturing capacity.
- Sterile injectable facilities.
- Experience filing Paragraph IV ANDAs.
- Commercial access to hospital group purchasing organizations.
- Ability to produce or license an alternative ceftobiprole process.
A challenger may initially pursue a limited label excluding patented bacteremia or endocarditis uses. That strategy could permit entry into skin infections or pneumonia before all use patents expire, subject to FDA labeling and patent constraints.
No major public Paragraph IV challenge or final settlement should be assumed without a confirmed FDA Orange Book entry, court docket, or company disclosure.
What patent litigation and settlements affect ceftobiprole?
Publicly disclosed litigation is a key valuation variable because an ANDA filing can convert patent uncertainty into a defined launch date. Relevant events include:
| Event |
Commercial implication |
| Paragraph IV notice |
Signals potential generic entry before patent expiry |
| Patent suit within 45 days |
May trigger a 30-month FDA approval stay |
| Claim construction or summary judgment |
Can materially change launch probability |
| Settlement agreement |
May establish an agreed generic entry date |
| License to a generic manufacturer |
Can convert litigation risk into controlled competition |
| Patent invalidity ruling |
Can remove a major barrier to early entry |
The absence of a widely reported dispute does not establish that the product is litigation-free. Patent status must be tracked through FDA listings, USPTO records, federal court dockets, and Basilea disclosures.
How strong is the ceftobiprole patent estate?
The estate is commercially meaningful but unlikely to be impenetrable.
Strength factors include:
- Multiple indications supporting method-of-use protection.
- QIDP-related extension of applicable protection.
- Complex sterile injectable manufacturing.
- Potential formulation and process claims.
- Clinical evidence directly supporting bacteremia use.
Weakness factors include:
- Prior non-U.S. approval and possible limits on U.S. regulatory exclusivity.
- Generic availability of competing MRSA therapies.
- Potential design-around routes for formulation and process claims.
- Narrow enforceability of method-of-use patents.
- Hospital pressure to use lower-cost antibiotics.
The strongest protection would be a valid, unexpired composition patent covering the active prodrug or a required pharmaceutical form. Formulation and process patents would provide secondary protection but may be more vulnerable to design-around strategies.
What generic launch scenarios exist?
Three launch scenarios are commercially plausible.
Full-label launch after patent expiry
A generic manufacturer enters with all FDA-approved indications once the relevant patents and exclusivity periods expire. This would cause the fastest price erosion.
Carved-out launch
A generic enters with one or more patented uses removed from its label. Initial competition may target skin infections or pneumonia while bacteremia and endocarditis remain protected.
Authorized or licensed generic
Basilea or a commercial partner licenses a generic manufacturer before full patent expiry. This could reduce litigation costs but would also accelerate price competition.
For a high-acuity intravenous antibiotic, conversion may be gradual because hospitals often maintain multiple suppliers, require formulary review, and prioritize supply reliability. Revenue erosion can still be severe once a second FDA-approved supplier establishes dependable inventory.
How does Zevtera compare with Basilea’s Cresemba?
Cresemba and Zevtera occupy different hospital treatment categories.
| Metric |
Zevtera |
Cresemba |
| Active ingredient |
Ceftobiprole medocaril |
Isavuconazonium sulfate |
| Therapeutic area |
Antibacterial |
Antifungal |
| Main approved use |
Serious bacterial infections |
Invasive aspergillosis and mucormycosis |
| Dosage forms |
Intravenous |
Intravenous and oral |
| Commercial concentration |
Hospital antibacterial departments |
Hospital and outpatient antifungal treatment |
| Generic threat |
Generic cephalosporins and MRSA agents |
Antifungal patent and formulation competition |
| Strategic role for Basilea |
U.S. launch and antibacterial growth |
Larger established revenue contributor |
Cresemba has the stronger commercial base because it has an oral formulation and a concentrated antifungal market. Zevtera provides diversification and growth but faces greater substitution pressure from inexpensive antibacterial therapies.
Key Takeaways
- Ceftobiprole medocaril sodium is marketed in the U.S. as Zevtera.
- The FDA approved Zevtera in 2024 for adult S. aureus bacteremia, including right-sided endocarditis, acute bacterial skin and skin-structure infections, and community-acquired bacterial pneumonia.
- The principal commercial opportunity is serious MRSA bacteremia and endocarditis.
- Vancomycin and daptomycin remain powerful competitors because of price, experience, and established hospital protocols.
- QIDP status strengthens U.S. protection but does not eliminate patent or generic-entry risk.
- The product’s financial trajectory depends on U.S. formulary adoption, infectious-disease physician use, and Basilea’s ability to convert clinical differentiation into hospital contracts.
- Zevtera is a growth product for Basilea, but Cresemba remains the company’s larger commercial asset.
- Generic entry may occur through full-label, carved-out, or licensed-generic strategies.
- A definitive loss-of-exclusivity date requires current Orange Book, USPTO, court-docket, and company-disclosure review.
FAQs About Ceftobiprole Medocaril Sodium
Is ceftobiprole medocaril sodium the same as Zevtera?
Yes. Ceftobiprole medocaril sodium is the active pharmaceutical ingredient and prodrug marketed in the United States under the Zevtera brand.
Is ceftobiprole active against MRSA?
Yes. Ceftobiprole has in-vitro activity against MRSA and is FDA approved for adult S. aureus bacteremia, including right-sided infective endocarditis.
Can ceftobiprole replace vancomycin?
It can be used as an alternative in selected patients, but its higher branded-drug cost and hospital stewardship controls limit broad replacement of generic vancomycin.
Does ceftobiprole have an oral formulation?
The U.S. Zevtera product is an intravenous formulation. The lack of an oral version limits outpatient and step-down treatment opportunities.
Is ceftobiprole a biologic or a biosimilar?
No. Ceftobiprole is a small-molecule antibacterial drug. Future competitors would generally pursue the ANDA generic-drug pathway rather than the biosimilar pathway.
References
- Basilea Pharmaceutica Ltd. (2024a). Zevtera U.S. prescribing information.
- Basilea Pharmaceutica Ltd. (2024b). Annual report 2023. Basel, Switzerland.
- Basilea Pharmaceutica Ltd. (2025). Annual report 2024. Basel, Switzerland.
- U.S. Food and Drug Administration. (2024a, March 14). FDA approves treatment for adults with bloodstream infections caused by Staphylococcus aureus.
- U.S. Food and Drug Administration. (2024b). Qualified infectious disease product designation and exclusivity provisions.
- U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations: Orange Book.
